Neogen Corporation (NEOG) Company Overview

Neogen Corporation is a Nasdaq-listed life-sciences and diagnostics company focused on protecting the food chain. Its products help food processors detect pathogens, allergens, toxins and sanitation failures; they also help livestock producers, veterinarians, laboratories and retailers manage animal health, biosecurity and productivity. The business is best understood as a portfolio of consumable tests, culture media, instruments, software, veterinary products and technical services rather than as a single diagnostic platform.

The company reports two operating segments: Food Safety and Animal Safety. Food Safety is now the strategic center of gravity, especially after the 2022 combination with 3M’s former Food Safety business. Animal Safety remains broad but is being simplified through divestitures. The FY2025 Form 10-K describes a global commercial footprint, direct operations in 28 countries outside the United States and distributor coverage in more than 100 countries.

Which customers and products define the business?

Why does Neogen matter in food safety?

Food producers are not buying a test merely to generate a laboratory result. They are buying speed, traceability, plant uptime, regulatory confidence and protection against recalls. Neogen’s food-safety portfolio spans sample collection, microbial testing, environmental monitoring and data management. That breadth matters because a plant can standardize more of its quality-control workflow with one supplier, while Neogen can sell consumables repeatedly after instruments and protocols are embedded.

Neogen earns most of its revenue by selling physical products: single-use test kits, culture media, reagents, sampling products, instruments, veterinary supplies and pest-control products. Service revenue comes mainly from laboratory and genomics work. The model therefore combines recurring consumables with lower-frequency equipment sales and technical services. Pricing power depends on test performance, regulatory acceptance, customer workflow integration and the cost of switching procedures—not on a formal subscription contract.

What is the revenue logic?

Which segment is the economic engine?

The strategic answer is clear: Food Safety supplies most revenue, the strongest current core growth and the products management wants to prioritize. Animal Safety still provides diversification and cash-generating brands, but the announced sale of Genomics shows management is willing to narrow the portfolio when an asset does not fit the desired return and leverage profile.

The latest official package is the quarter ended February 28, 2026, Neogen’s fiscal third quarter. Revenue declined on a reported basis because divestitures, discontinued products and Animal Safety disruptions outweighed Food Safety growth. Yet the quarter also showed sequential improvement in adjusted profitability and positive free cash flow. The central analytical tension is that Neogen’s core Food Safety demand is improving while the company is still carrying integration costs, manufacturing inefficiencies and debt from the 3M transaction.

How did revenue, margins and earnings move?

The Q3 FY2026 earnings release raised full-year revenue guidance to $857M-$860M and maintained adjusted EBITDA guidance near $175M. Those targets imply that management expected the fourth quarter to preserve Food Safety momentum while containing Animal Safety and integration pressures.

What does cash generation reveal?

Quarterly operating cash flow was $22.7M and free cash flow was $11.1M. For the first nine months of FY2026, the Form 10-Q reported $53.0M of operating cash flow and $47.3M of capital spending, leaving only $5.7M of simple operating cash flow less capital expenditures. That thin conversion is understandable during a manufacturing transition, but it is not yet the steady-state cash profile investors would want from a consumables-heavy diagnostics company.

Neogen’s history matters because the company changed from a smaller, acquisition-driven food and animal safety supplier into a much larger global food-safety platform. The 3M Food Safety combination expanded product breadth and geographic reach, but it also introduced integration complexity, debt and manufacturing dependencies. Management’s current reset is therefore not simply a cost program; it is an attempt to complete the operating model promised by the transaction while selling assets that distract from the core.

Which turning points still shape the company?

1. 1982

   Operations began in Lansing, establishing the long-running strategy of serving practical food and animal safety problems with applied diagnostics.
2. December 2021

   Neogen announced the combination with 3M’s Food Safety business, aiming to create a larger global pure-play food-safety company.
3. September 2022

   The 3M Food Safety merger closed, adding Petrifilm, Clean-Trace and a customer base exceeding 100,000 end users across more than 60 countries.
4. FY2025

   A $1,059.3M goodwill impairment exposed the gap between transaction expectations and realized operating performance; the company also reported material weaknesses in internal control.
5. August 2025

   Mike Nassif became CEO and President, bringing a renewed emphasis on commercial execution, portfolio discipline, operational metrics and improved profitability.
6. March 2026

   Neogen agreed to sell Genomics to Zoetis for $160.0M, with expected net proceeds of about $140.0M primarily directed to debt reduction.

The result is a more focused strategic identity: Neogen wants to be judged primarily on food-safety growth, manufacturing reliability, gross-margin recovery and cash conversion. The Genomics sale announcement makes that priority explicit.

Neogen does not possess a single monopoly-like moat. Its advantage is a system of complementary resources: a broad portfolio, recurring consumables, global distribution, technical service, embedded testing procedures, regulatory familiarity and proprietary formulations. The FY2025 filing says competition is intense within individual categories but notes that no single rival pursues the same breadth across disposable tests, culture media, veterinary pharmaceuticals and instruments.

Where is the moat strongest?

The best evidence of customer stickiness is operational. A validated microbiology method can be written into plant procedures, quality manuals and staff training. Replacing it may require comparative studies, documentation changes and new instrument workflows. That does not eliminate competition, but it raises the practical cost of switching when the incumbent performs reliably.

Who competes with Neogen?

Neogen has adequate liquidity, but leverage still limits strategic freedom. At February 28, 2026, cash was $159.9M and total debt was $800.0M, down from $902.4M at May 31, 2025. The reduction followed the Cleaners and Disinfectants divestiture and $100.0M of debt repayments during the first nine months of FY2026. Available revolver capacity was $198.3M after letters of credit.

What do the balance sheet and capital allocation show?

Why did FY2025 look so weak?

FY2025 revenue was $894.7M, down 3% from FY2024. Gross profit was $421.4M, but a $1,059.3M goodwill impairment drove a $1,092.0M net loss. The impairment was non-cash, yet it was economically meaningful: it signaled that expected cash flows from acquired assets were no longer sufficient to support the original carrying value. Interest expense of $71.6M also showed the recurring cost of the transaction-funded capital structure.

Management’s stated objective was net debt to adjusted EBITDA below three times by the end of calendar 2026. The balance-sheet thesis therefore depends on both sides of the ratio: proceeds must reduce debt, and operating execution must preserve or grow adjusted EBITDA.

Neogen has a conventional single-class common equity structure rather than founder or family control. That makes the company institutionally governed: large asset managers and specialist funds can influence director elections, executive compensation and the urgency of operational improvement, but no disclosed shareholder has unilateral voting control.

Which holders have the largest disclosed positions?

The 2025 proxy statement used 217.30M shares outstanding as of August 26, 2025. The ownership profile indicates that institutional investors collectively have strong influence, while insider economic ownership is modest.

What changed in leadership?

The CEO appointment is strategically important because the company is moving from acquisition integration toward measurable execution. Management has emphasized solutions-based selling, standardized commercial processes, supplier qualification, sales and operations planning, innovation and disciplined resource allocation. Researchers should compare those priorities with actual core growth, margin and cash-flow outcomes rather than relying on adjusted targets alone.

Neogen’s opportunity is not dependent on a single new product. It comes from improving the productivity of a large installed portfolio in markets supported by stricter food-safety expectations, global supply-chain traceability and customer demand for faster, simpler testing. The company can create value through organic growth, mix improvement and better execution even without another major acquisition.

Which growth drivers could change the earnings profile?

The company’s stated purpose and values are relevant only insofar as they support trusted diagnostics. Responsibility, consistency and integrity are commercial assets in food safety because customers rely on repeatable results and documented procedures. Neogen employed 78 scientists and support staff in research and development at May 31, 2025, while FY2025 R&D expense was $21.1M. The challenge is converting that scientific base into products that raise customer productivity and earn attractive returns.

The largest risks are linked rather than independent. Manufacturing delays can reduce revenue, increase inventory write-offs and compress gross margin. Lower EBITDA can then slow deleveraging and increase valuation sensitivity to interest rates. At the same time, food-safety customers demand reliability, so a supply disruption can affect both current sales and long-term trust.

Which risks have the clearest financial transmission?

Which operating metrics should researchers track?

A DCF for Neogen should not extrapolate the FY2025 GAAP loss or the Q3 FY2026 adjusted margin mechanically. The company is in a transition period where reported earnings contain unusually large impairment, amortization, integration and restructuring effects, while cash flow contains elevated manufacturing investment. The useful valuation question is what the normalized Food Safety platform can earn after transfer costs fall and leverage declines.

Which variables drive intrinsic value?

For comparable-company work, Neogen sits between diagnostics, laboratory consumables, food-safety testing and animal-health suppliers. No single peer perfectly matches its mix. Analysts should therefore avoid applying a premium multiple based solely on recurring consumables without adjusting for leverage, integration risk and the remaining gap between adjusted and GAAP profitability.